Treat the first patient with BEAM-101 in the BEACON trial
Delivered after the deadline
AI-assessed · human review in progress Found and assessed by AI from the cited sources. Shown with its evidence; it is not counted in any Kept Score until confirmed.
- Announced
- 8 Nov 2023
- Due
- 31 Dec 2023
- Delivered
- January 2024
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“The first patient in the trial is expected to be treated with BEAM-101 by year-end 2023.”
What we found
Evidence strength A What the grades mean
The company announced in January 2024 that the first patient in the BEACON trial had been dosed, missing the year-end 2023 target.
-
A Beam Therapeutics Inc. 10-K filed 2024-02-27
“In January 2024, we announced that the first patient in our Phase 1/2 clinical trial designed to assess the safety and efficacy of BEAM-101 for the treatment of sickle cell disease, which we refer to as our BEACON trial, has been dosed” ✓ confirmed on the page
Market reaction: the shares moved +9.9% against the S&P 500 over the three sessions around the disclosure (26 Feb 2024 to 29 Feb 2024). What this measures
Checked 2 Oct 2026.
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Product other
- Indicative materiality
- Low rules
- Action
- Treat
- Deliverable
- BEAM-101 treatment
- Language
- Expected (“expects”, “plans”)
- In the company’s control
- High
- Specificity
- High
- Depends on
- Customer
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Gemini (Google), read the company's later filings and recorded the outcome with a quoted passage.
- Second check: disagreesClaude (Anthropic) re-read the evidence blind and read it as “Met”.
- Tie-breakA stronger model read the evidence and both earlier answers, without knowing which was recorded, and reads it as “no_evidence”.
Not yet confirmed. Shown on the record, but it will not count in any score until it is confirmed. How verification works
Are you Beam Therapeutics Inc.? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2023-BEAM-003253 · Corrections policy